High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients
about
cGMP-phosphodiesterase inhibition enhances photic responses and synchronization of the biological circadian clock in rodents3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissuesPhosphodiesterase 11 (PDE11) regulation of spermatozoa physiologyVirtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis.The protein kinase A pathway-regulated transcriptome of endometrial stromal fibroblasts reveals compromised differentiation and persistent proliferative potential in endometriosisDevelopment of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinomaNanoethosomal transdermal delivery of vardenafil for treatment of erectile dysfunction: optimization, characterization, and in vivo evaluation.The therapeutic dilemma: how to use tadalafil.Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.Phosphodiesterase 11: a brief review of structure, expression and function.Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?Oral phosphodiesterase-5 inhibitors and sperm functions.Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.Erectile dysfunction and its management in patients with diabetes mellitus.Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.Cyclic nucleotide phosphodiesterases in Drosophila melanogaster.Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia.The properties of phosphodiesterase 11A4 GAF domains are regulated by modifications in its N-terminal domain.Inhibitory effect of sildenafil on the human isolated seminal vesicle.JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.Phosphodiesterase type 5 and cancers: progress and challenges.
P2860
Q27302892-D3078BEA-49C5-4C34-BD55-5B64DFE6F2CEQ28242677-9D1410CA-ACC7-498C-A152-3AB2CC3FDF1DQ28242689-552FD14C-349C-451F-ABB2-EF0069338E34Q33525137-CF68A5B1-DCCE-4CBB-9B9F-BC3836202921Q33552839-9F0C48DC-738D-4855-BAE6-55D18CEC1742Q33735545-384A3143-ED2C-4CE6-9E5E-313C879852D2Q34538482-6DAE034B-93F3-4F7B-A045-54810F4E1CE8Q35067627-3BFAA4CE-EEB0-4AC6-AF61-1B3BD9B44444Q35851963-5A40AF7D-BD1B-468A-AE28-82791EDE1764Q36291011-274519C5-6DB8-42F7-8FC0-0059B7A39707Q36334968-489F3654-5DF7-48EC-B59F-853B25C95B7BQ36361603-FECF37E4-6A20-44F0-A01F-E4513756EE2BQ36689825-49C99828-9DEF-46F2-8992-A34C80B823DFQ37205812-9C5E9AB2-EAFD-4B15-BA47-C7700EC2E6F9Q37947681-2854666A-0F2B-4EEC-9136-89D798A8798EQ38047228-CDE6B7F0-8F1F-4C41-8EBA-5EDD02D5FFD4Q38107001-F2E2FFD3-DBC1-43DD-9D09-7B5DE4E1EECDQ38222740-E78DC4B6-1625-40D1-9A69-36C306AF491CQ38615555-5D2D57F9-82AF-4BC7-8B4D-7DEECAE446A2Q39790023-EF17E436-15EE-4AED-BF6A-3473BE23E138Q41585040-EDB51456-EA83-4B8B-871F-77EE69A3A4DEQ41889474-CB051686-FC3C-4BA9-B9BD-386AF0502A4BQ42364583-8234A74C-94E5-4A7A-A7DF-A7E592CC18CFQ46611139-7689127D-8443-42A9-ADEA-CA1BF2D4CBC3Q46724207-EDA8B88A-610F-4B1B-90DA-FF7565FE461FQ46916857-DAA9A3E7-7D2B-4EBD-B72A-42F2B25712C4Q46983898-7016556D-6C9C-4EA5-9997-DDC8CF7A8389Q47171803-2B5D8148-B13C-42EE-976F-92CDBF9081AC
P2860
High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@ast
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@en
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@nl
type
label
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@ast
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@en
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@nl
prefLabel
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@ast
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@en
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@nl
P2093
P2860
P356
P1476
High biochemical selectivity o ...... 1A4 cross-reaction in patients
@en
P2093
P2860
P2888
P356
10.1038/SJ.IJIR.3901283
P407
P577
2005-01-01T00:00:00Z
P5875
P6179
1042850901